These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 19698585)

  • 21. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
    Davidson JR; Meoni P; Haudiquet V; Cantillon M; Hackett D
    Depress Anxiety; 2002; 16(1):4-13. PubMed ID: 12203668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative efficacy of antidepressants.
    Kasper S; Fuger J; Möller HJ
    Drugs; 1992; 43 Suppl 2():11-22; discussion 22-3. PubMed ID: 1378369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Venlafaxine: new preparation. Just another antidepressant.
    Prescrire Int; 1998 Aug; 7(36):112-4. PubMed ID: 10342950
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and tolerance profile of venlafaxine.
    Danjou P; Hackett D
    Int Clin Psychopharmacol; 1995 Mar; 10 Suppl 2():15-20. PubMed ID: 7622813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Levomilnacipran for the treatment of major depressive disorder: a review.
    Asnis GM; Henderson MA
    Neuropsychiatr Dis Treat; 2015; 11():125-35. PubMed ID: 25657584
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia.
    Benkert O; Gründer G; Wetzel H; Hackett D
    J Psychiatr Res; 1996; 30(6):441-51. PubMed ID: 9023787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Therapeutic action lag time and resistance to treatment].
    Peretti CS
    Encephale; 1999 Jun; 25 Spec No 2():49-54. PubMed ID: 10434159
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches.
    Wohlreich MM; Martinez JM; Mallinckrodt CH; Prakash A; Watkin JG; Fava M
    J Clin Psychopharmacol; 2005 Dec; 25(6):552-60. PubMed ID: 16282837
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The importance of long-term tolerability in achieving recovery.
    Baldwin DS
    Int J Psychiatry Clin Pract; 2006; 10 Suppl 1():31-7. PubMed ID: 24931542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients.
    Schweizer E; Feighner J; Mandos LA; Rickels K
    J Clin Psychiatry; 1994 Mar; 55(3):104-8. PubMed ID: 8071246
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antidepressant Drugs Effects on Blood Pressure.
    Calvi A; Fischetti I; Verzicco I; Belvederi Murri M; Zanetidou S; Volpi R; Coghi P; Tedeschi S; Amore M; Cabassi A
    Front Cardiovasc Med; 2021; 8():704281. PubMed ID: 34414219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quetiapine : A Review of its Use in Schizophrenia.
    Gunasekara NS; Spencer CM
    CNS Drugs; 1998 Apr; 9(4):325-40. PubMed ID: 27521016
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Global Benefit-risk Evaluation of Antidepressant Action: Comparison of Pooled Data for Venlafaxine, SSRIs, and Placebo.
    Entsuah R; Gao B
    CNS Spectr; 2002 Dec; 7(12):882-888. PubMed ID: 12766699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression.
    Shrivastava RK; Cohn C; Crowder J; Davidson J; Dunner D; Feighner J; Kiev A; Patrick R
    J Clin Psychopharmacol; 1994 Oct; 14(5):322-9. PubMed ID: 7806687
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reboxetine: a review of efficacy and tolerability.
    Delgado PL; Michaels T
    Drugs Today (Barc); 1999 Sep; 35(9):725-37. PubMed ID: 12973469
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia.
    Tzanakaki M; Guazzelli M; Nimatoudis I; Zissis NP; Smeraldi E; Rizzo F
    Int Clin Psychopharmacol; 2000 Jan; 15(1):29-34. PubMed ID: 10836283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Milnacipran. A review of its use in depression.
    Spencer CM; Wilde MI
    Drugs; 1998 Sep; 56(3):405-27. PubMed ID: 9777315
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative efficacy and tolerability among different selective serotonin re-uptake inhibitors and venlafaxine in a naturalistic setting.
    Arias F; Padín JJ; Gilaberte I; Varillas P; Sánchez R; Gómez S; García D
    Int J Psychiatry Clin Pract; 1998; 2(4):255-60. PubMed ID: 24927088
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression.
    Davis R; Whittington R; Bryson HM
    Drugs; 1997 Apr; 53(4):608-36. PubMed ID: 9098663
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness.
    Dechant KL; Clissold SP
    Drugs; 1991 Feb; 41(2):225-53. PubMed ID: 1709852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.